Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Early results ‘encouraging’ for CAR NKT cells in neuroblastoma
Key clinical point: Chimeric antigen receptor natural killer T (CAR NKT) cells have shown early promise in patients with relapsed/refractory neuroblastoma.
Major finding: The CAR NKT cells expanded in vivo and localized to tumors, one of three patients treated achieved a response at 4 weeks, and there were no adverse events associated with the CAR NKT cells.
Study details: Phase 1 trial of three patients with relapsed/refractory neuroblastoma.
Disclosures: The research was funded by Kuur Therapeutics, Alex’s Lemonade Stand Foundation for Childhood Cancer, the American Cancer Society, Cookies for Kids’ Cancer Foundation, and the Cancer Prevention and Research Institute of Texas. Four researchers are coinventors on pending patent applications for NKT cells in cancer immunotherapy that have been licensed to Kuur Therapeutics for commercial development.
Heczey A et al. Nat Med. 2020 Oct 12. doi: 10.1038/s41591-020-1074-2.